^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ZW191

    i
    Other names: ZW191, ZW 191, ZW-191
    Company:
    Zymeworks
    Drug class:
    Topoisomerase I inhibitor, Folate receptor 1-targeted antibody-drug conjugate
    Related drugs:
    2ms
    ZWI-ZW191-101: A Study of ZW191 in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=145, Active, not recruiting, Zymeworks BC Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ZW191
    2ms
    ZW191, a FRα-targeted topoisomerase 1 inhibitor ADC with a differentiated antitumor efficacy and tolerability profile. (PubMed, Clin Cancer Res)
    ZW191 demonstrates favourable preclinical efficacy and tolerability. This differentiated profile is supported by initial clinical data, potentially positioning ZW191 to meaningfully improve responses and substantially widen the targetable patient population over standard of care.
    Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • paclitaxel • Elahere (mirvetuximab soravtansine-gynx) • ZW191
    over1year
    A Study of ZW191 in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=145, Recruiting, Zymeworks BC Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    ZW191
    almost2years
    A Study of ZW191 in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=145, Not yet recruiting, Zymeworks BC Inc.
    New P1 trial • Metastases
    |
    ZW191